コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 efosine has not been evaluated for pediatric cutaneous leishmaniasis.
2 Glucantime((R)) (meglumine antimoniate) for cutaneous leishmaniasis.
3 ned immunotherapeutic using a mouse model of cutaneous leishmaniasis.
4 intracellular protozoan parasite that causes cutaneous leishmaniasis.
5 hmaniasis, mucosal leishmaniasis and diffuse cutaneous leishmaniasis.
6 ells in determining the outcome of New World cutaneous leishmaniasis.
7 NF) can provide protection against New World cutaneous leishmaniasis.
8 understanding pathogenesis and protection in cutaneous leishmaniasis.
9 augmentation as an intervention in American cutaneous leishmaniasis.
10 tection against both Old World and New World cutaneous leishmaniasis.
11 oth a murine and a nonhuman primate model of cutaneous leishmaniasis.
12 ere investigated in an experimental model of cutaneous leishmaniasis.
13 for the synthesis of drugs effective against cutaneous leishmaniasis.
14 the treatment of parasitologically confirmed cutaneous leishmaniasis.
15 ration of PCR into diagnostic strategies for cutaneous leishmaniasis.
16 IgG antibodies in patients with visceral and cutaneous leishmaniasis.
17 n-activating gene(-/-) mice from progressive cutaneous leishmaniasis.
18 uce protective immunity in a murine model of cutaneous leishmaniasis.
19 uman primate (rhesus monkey) models of human cutaneous leishmaniasis.
20 mononuclear cells of patients with American cutaneous leishmaniasis.
21 in Leishmania major, the causative agent for cutaneous leishmaniasis.
22 and fully effective in this primate model of cutaneous leishmaniasis.
23 cells play a protective role in immunity to cutaneous leishmaniasis.
24 e etiological agent of cutaneous and diffuse cutaneous leishmaniasis.
25 ficient to ameliorate disease in established cutaneous leishmaniasis.
26 le is known about their roles in non-healing cutaneous leishmaniasis.
27 uring the dosing period in a murine model of cutaneous leishmaniasis.
28 ities for continued optimization for HAT and cutaneous leishmaniasis.
29 te of the order Kinetoplastida causing human cutaneous leishmaniasis.
30 h problem and to achieve enhanced control of cutaneous leishmaniasis.
31 bs could serve as an intervention to prevent cutaneous leishmaniasis.
32 insights into immune regulation in New World cutaneous leishmaniasis.
33 rce for CHIM studies of sand fly transmitted cutaneous leishmaniasis.
34 or of Leishmania major, a causative agent of cutaneous leishmaniasis.
35 ol the parasite load and alter the course of cutaneous leishmaniasis.
36 ssociated with increased pathology in murine cutaneous leishmaniasis.
37 an absence of ulceration and necrosis during cutaneous leishmaniasis.
38 hmania major, one of the causative agents of cutaneous leishmaniasis.
39 anials and are more prone to develop chronic cutaneous leishmaniasis.
40 ses and, thereby, contributes to the cure of cutaneous leishmaniasis.
41 a, and south Asia had the highest DALYs from cutaneous leishmaniasis.
42 Leishmania major causes cutaneous leishmaniasis.
43 alence of sequalae of both acute and chronic cutaneous leishmaniasis.
44 apeutic target in both localized and diffuse cutaneous leishmaniasis.
45 between localized and drug-resistant diffuse cutaneous leishmaniasis.
46 arasites that cause unique clinical forms of cutaneous leishmaniasis.
47 esion size and parasite burden in a model of cutaneous leishmaniasis.
48 tion for treating individuals suffering from cutaneous leishmaniasis.
49 sepsis and ameliorated pathological signs of cutaneous leishmaniasis.
53 uviana endemicity were screened for American cutaneous leishmaniasis (ACL) infection by established P
54 robe, Gimblet et al. (2017) demonstrate that cutaneous leishmaniasis alters the human skin microbiota
56 etely dispensable for clinical resolution of cutaneous leishmaniasis and for long-term persistence of
57 investigated the role of skin microbiota in cutaneous leishmaniasis and found that human patients in
58 ania major, a protozoan parasite that causes cutaneous leishmaniasis and lacks TS and the TS product
59 red a therapeutic strategy for patients with cutaneous leishmaniasis and other inflammatory skin dise
60 hese results have clinical ramifications for cutaneous leishmaniasis and other skin diseases associat
61 ide a new perspective on the pathogenesis of cutaneous leishmaniasis and protozoan parasite-host inte
62 portant implications for the epidemiology of cutaneous leishmaniasis and suggest a vaccination strate
63 man microbiome can shape disease outcomes in cutaneous leishmaniasis and suggest pathways toward host
64 kin Mphi and DC are infected sequentially in cutaneous leishmaniasis and that they play distinct role
65 pacity to confer complete protection against cutaneous leishmaniasis and to prevent the establishment
66 ntibody titers were detected in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patie
68 T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (mal
69 or Arg reduces infection severity in murine cutaneous leishmaniasis, and imatinib treatment results
70 ania chagasi in dermal scrapings of atypical cutaneous leishmaniasis, and L. mexicana from lesion asp
71 rican trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated
72 Visceral leishmaniasis and severe forms of cutaneous leishmaniasis are managed by systemic treatmen
73 may improve the prognosis for patients with cutaneous leishmaniasis, as well as for other inflammato
75 l global burden and assessed the equality of cutaneous leishmaniasis burden across different countrie
76 ward Th2 responses, which are detrimental in cutaneous leishmaniasis but beneficial in acute schistos
77 major and Leishmania braziliensis both cause cutaneous leishmaniasis, but the former kills BALB/c mic
83 umine antimoniate for treatment of pediatric cutaneous leishmaniasis caused by Leishmania (Viannia) s
84 ailure of pentavalent antimony treatment for cutaneous leishmaniasis caused by Leishmania braziliensi
85 mycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tu
90 le in the susceptibility and pathogenesis of cutaneous leishmaniasis caused by the New World species,
94 almost all blood cells (pancytopenia), or as cutaneous leishmaniasis, characterized by ulcerative or
95 t contribute to the efficacy of treatment of cutaneous leishmaniasis (CL) are not fully understood.
96 g or in the chronic immunopathology of human cutaneous leishmaniasis (CL) are not well understood.
98 oal was to identify genetic risk factors for cutaneous leishmaniasis (CL) caused by Leishmania brazil
100 saliva in 264 individuals, from an area for cutaneous leishmaniasis (CL) caused by Leishmania brazil
104 fection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major.
107 R methods for diagnosis of acute and chronic cutaneous leishmaniasis (CL) in an area of Colombia wher
110 uvant significantly reduced the incidence of cutaneous leishmaniasis (CL) in Ecuadorian children, com
111 5303 is a risk factor for the development of cutaneous leishmaniasis (CL) in Leishmania guyanensis-in
119 ntrast, protective immunity against nonfatal cutaneous leishmaniasis (CL) is well defined and mediate
122 n of Leishmania donovani in Sri Lanka causes cutaneous leishmaniasis (CL) rather than more common vis
124 role played by natural killer (NK) cells in cutaneous leishmaniasis (CL) remains poorly understood.
125 he clinical course of and immune response to cutaneous leishmaniasis (CL) treated with pentavalent an
126 08 household contacts (HCs) of patients with cutaneous leishmaniasis (CL) was established in 2010 in
127 biopsy specimens from patients with chronic cutaneous leishmaniasis (CL) were compared to those in b
128 of efficacy has been documented in Old World cutaneous leishmaniasis (CL), and different cure rates a
129 e been implicated in progressive symptomatic cutaneous leishmaniasis (CL), but their potential partic
130 IFN)-y is indispensable in the resolution of cutaneous leishmaniasis (CL), while the Th2 cytokines IL
137 gumentary leishmaniasis (ATL) (also known as cutaneous leishmaniasis [CL]) is caused by various speci
138 tomatic or cause mild or severe skin ulcers (cutaneous leishmaniasis [CL]), limited or disseminated l
139 mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis, CpG treatment similarly exhibit
142 Global and national data on the burden of cutaneous leishmaniasis disease are pivotal to promote f
143 e considered a strategy for the treatment of cutaneous leishmaniasis disease in combination with anti
144 mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis due to Leishmania braziliensis a
147 DNA- and protein- based vaccines against cutaneous leishmaniasis due to Leishmania major were eva
151 inants influencing therapy response in human cutaneous leishmaniasis, focusing on the intricate host-
153 nated mice was abrogated in vector-initiated cutaneous leishmaniasis, highlighting the importance of
154 the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent stru
155 results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enh
157 /kg/day for 5 days effects a radical cure of cutaneous leishmaniasis in Balb/c mice, as evidenced by
158 is required for spontaneous healing of acute cutaneous leishmaniasis in C57BL/6 mice and for lifelong
159 shmaniasis and, to a lesser extent, atypical cutaneous leishmaniasis in Central and South America.
160 amensis, the predominant etiologic agent for cutaneous leishmaniasis in Colombia, is characterized by
162 he parasite and its vector, the pathology of cutaneous leishmaniasis in humans and also the developme
163 Similar proportions of males and females had cutaneous leishmaniasis in most countries with a high in
164 lecular epidemiology of the zoonotic disease cutaneous leishmaniasis in Peru and Bolivia through a jo
166 ion with P8 PGLC provides protection against cutaneous leishmaniasis in susceptible BALB/c mice.
170 prints suggests that the present epidemic of cutaneous leishmaniasis in Timargara camp may be due to
171 is a promising vaccination strategy against cutaneous leishmaniasis inducing long-term protection ag
178 tic method for visceral leishmaniasis, while cutaneous leishmaniasis is commonly diagnosed by microsc
182 al stage drug candidate for the treatment of cutaneous leishmaniasis, is a synthetic nonapeptide insp
184 ania (Viannia) braziliensis causes localized cutaneous leishmaniasis (LCL) and mucocutaneous leishman
185 h DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an a
187 a (Viannia) braziliensis can cause localized cutaneous leishmaniasis (LCL), which heals spontaneously
190 t is highly expressed in human patients with cutaneous leishmaniasis lesions and promotes granzyme B-
191 rated that the major sources of Il15 mRNA in cutaneous leishmaniasis lesions are neutrophils and macr
192 clinical symptoms ranging from self-healing cutaneous leishmaniasis lesions to fatal visceral diseas
193 being able to acquire parasites from active cutaneous leishmaniasis lesions, sustain mature infectio
196 ed from mononuclear cells from patients with cutaneous leishmaniasis (Lm), once loaded with live meta
198 ectins, the immune pathology associated with cutaneous leishmaniasis might be ameliorated without com
199 tical for IL-12 production and resistance to cutaneous leishmaniasis, others suggest that this pathwa
201 veral of these Ags in PBMC from self-healing cutaneous leishmaniasis patients infected with either Le
205 or Leishmania major, which cause visceral or cutaneous leishmaniasis, respectively, elicited dramatic
206 untries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghanistan (87.0
207 s is an important etiological agent of human cutaneous leishmaniasis that accounts for more than 8% o
211 nts with one to five ulcerative lesions from cutaneous leishmaniasis to receive a cream containing 15
214 , the global mean age-standardised DALYs for cutaneous leishmaniasis was 0.58 per 100 000 people.
215 infection, the inflammatory response during cutaneous leishmaniasis was evaluated in 129Sv/C57BL/6-r
216 e development of protective immunity against cutaneous leishmaniasis, we analyzed the course of cutan
218 2-12 years with parasitologically confirmed cutaneous leishmaniasis were randomized to directly obse
219 ishmaniasis are significantly lower than for cutaneous leishmaniasis; whether this is due to the high
220 e causative agent of Old World anthroponotic cutaneous leishmaniasis, which is characterized by lesio
221 d for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect p